Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.

Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP.

BMC Psychiatry. 2013 May 22;13:143. doi: 10.1186/1471-244X-13-143.

2.

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.

Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, Gomez JC.

Schizophr Res. 2013 Nov;150(2-3):434-41. doi: 10.1016/j.schres.2013.08.020. Epub 2013 Sep 12.

PMID:
24035403
3.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
4.

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.

Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N; HBBI Study Group.

J Clin Psychopharmacol. 2011 Jun;31(3):349-55. doi: 10.1097/JCP.0b013e318218dcd5.

PMID:
21508856
5.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
6.

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.

Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, Brenner R, Rayle TJ, Nisenbaum L, Zhao F, Gomez JC.

BMC Psychiatry. 2014 Dec 10;14:351. doi: 10.1186/s12888-014-0351-3.

7.
8.

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM.

Schizophr Res. 2014 Aug;157(1-3):112-9. doi: 10.1016/j.schres.2014.05.040. Epub 2014 Jul 1. Erratum in: Schizophr Res. 2014 Oct;159(1):256.

PMID:
24994555
9.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

10.
11.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
12.

Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia.

Kinon BJ, Gómez JC.

Neuropharmacology. 2013 Mar;66:82-6. doi: 10.1016/j.neuropharm.2012.06.002. Epub 2012 Jun 18.

PMID:
22722029
13.

Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.

Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M.

Psychopharmacol Bull. 2010;43(2):45-66. Review.

PMID:
21052042
14.

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.

Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC.

Schizophr Res Treatment. 2014;2014:758212. doi: 10.1155/2014/758212. Epub 2014 Mar 19.

15.

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD.

Psychopharmacology (Berl). 2006 Dec;189(2):259-66. Epub 2006 Oct 21.

PMID:
17058105
16.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
17.

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Swainston Harrison T, Perry CM.

Drugs. 2004;64(15):1715-36. Review.

PMID:
15257633
18.

Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.

Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG.

J Clin Psychiatry. 2007 Jan;68(1):29-36.

PMID:
17284127
19.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
20.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

Supplemental Content

Support Center